LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset - HMS LINCS Database

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20358)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 5 of 66
Next
>>
>
101 to 125 of 1647 records
per page:

Small Molecule	barcode	cell_count	frac_dead	corpse_count	cell_count_dead	row	column	agent	concentration	role	timepoint	replicate	cell_line	dead_count	fraction_dead	cell_count__time0	dead_count__time0	cell_count__ctrl	dead_count__ctrl	fraction_dead__ctrl	increase_fraction_dead	GRvalue
Dasatinib	180615_MC_06	7103	0.0301	65	151	6	6	Dasatinib	0.099799999	treatment	72	1	MCF10A-GM_2	216	0.0295	586.3	196.0	12428	298.5	0.0234	0.00611	0.7615
Dasatinib	180615_MC_06	7635	0.0345	80	186	6	16	Dasatinib	0.099799999	treatment	72	1	MCF10A-GM_3	266	0.0337	586.3	196.0	12428	298.5	0.0234	0.01027	0.7906
Dasatinib	180615_MC_07	8319	0.0219	34	149	3	16	Dasatinib	0.099799999	treatment	72	1	MCF10A-GM_4	183	0.0215	586.3	196.0	12428	298.5	0.0234	-0.00187	0.8258
Dasatinib	180615_MC_07	8852	0.0246	34	185	5	11	Dasatinib	0.099799999	treatment	72	1	MCF10A-GM_5	219	0.0241	586.3	196.0	12428	298.5	0.0234	0.00074	0.8517
Dasatinib	180615_MC_07	7759	0.0361	99	185	10	6	Dasatinib	0.099799999	treatment	72	1	MCF10A-GM_6	284	0.0353	586.3	196.0	12428	298.5	0.0234	0.01191	0.7972
Dasatinib	180615_MC_08	9328	0.0280	81	182	4	4	Dasatinib	0.099799999	treatment	72	1	MCF10A-GM_7	263	0.0274	586.3	196.0	12428	298.5	0.0234	0.00402	0.8739
Dasatinib	180615_MC_08	8740	0.0292	61	196	6	3	Dasatinib	0.099799999	treatment	72	1	MCF10A-GM_8	257	0.0286	586.3	196.0	12428	298.5	0.0234	0.00517	0.8464
Dasatinib	180615_MC_08	8665	0.0280	47	197	12	8	Dasatinib	0.099799999	treatment	72	1	MCF10A-GM_9	244	0.0274	586.3	196.0	12428	298.5	0.0234	0.00399	0.8428
Dasatinib	180615_MC_06	2279	0.0656	55	98	8	14	Dasatinib	0.316033316	treatment	72	1	MCF10A-GM_1	153	0.0629	586.3	196.0	12428	298.5	0.0234	0.03951	0.3609
Dasatinib	180615_MC_06	2304	0.0572	38	96	10	20	Dasatinib	0.316033316	treatment	72	1	MCF10A-GM_2	134	0.0550	586.3	196.0	12428	298.5	0.0234	0.03156	0.3643
Dasatinib	180615_MC_06	2952	0.0511	40	113	12	12	Dasatinib	0.316033316	treatment	72	1	MCF10A-GM_3	153	0.0493	586.3	196.0	12428	298.5	0.0234	0.02588	0.4432
Dasatinib	180615_MC_07	2572	0.0784	106	104	4	20	Dasatinib	0.316033316	treatment	72	1	MCF10A-GM_4	210	0.0755	586.3	196.0	12428	298.5	0.0234	0.05209	0.3988
Dasatinib	180615_MC_07	2585	0.0429	25	87	9	17	Dasatinib	0.316033316	treatment	72	1	MCF10A-GM_5	112	0.0415	586.3	196.0	12428	298.5	0.0234	0.01813	0.4004
Dasatinib	180615_MC_07	2699	0.0594	47	116	12	9	Dasatinib	0.316033316	treatment	72	1	MCF10A-GM_6	163	0.0570	586.3	196.0	12428	298.5	0.0234	0.03356	0.4142
Dasatinib	180615_MC_08	3083	0.0560	25	149	3	5	Dasatinib	0.316033316	treatment	72	1	MCF10A-GM_7	174	0.0534	586.3	196.0	12428	298.5	0.0234	0.03003	0.4575
Dasatinib	180615_MC_08	3011	0.0500	10	141	7	4	Dasatinib	0.316033316	treatment	72	1	MCF10A-GM_8	151	0.0478	586.3	196.0	12428	298.5	0.0234	0.02436	0.4497
Dasatinib	180615_MC_08	3456	0.0611	64	151	14	17	Dasatinib	0.316033316	treatment	72	1	MCF10A-GM_9	215	0.0586	586.3	196.0	12428	298.5	0.0234	0.03517	0.4958
Dasatinib	180615_MC_06	1241	0.1074	35	102	3	22	Dasatinib	0.997999808	treatment	72	1	MCF10A-GM_1	137	0.0994	586.3	196.0	12428	298.5	0.0234	0.07602	0.1855
Dasatinib	180615_MC_06	2005	0.1060	89	133	4	12	Dasatinib	0.997999808	treatment	72	1	MCF10A-GM_2	222	0.0997	586.3	196.0	12428	298.5	0.0234	0.07629	0.3219
Dasatinib	180615_MC_06	1704	0.0595	9	93	11	3	Dasatinib	0.997999808	treatment	72	1	MCF10A-GM_3	102	0.0565	586.3	196.0	12428	298.5	0.0234	0.03308	0.2740
Dasatinib	180615_MC_07	1639	0.1183	60	141	6	12	Dasatinib	0.997999808	treatment	72	1	MCF10A-GM_4	201	0.1092	586.3	196.0	12428	298.5	0.0234	0.08584	0.2628
Dasatinib	180615_MC_07	1236	0.1110	43	99	7	11	Dasatinib	0.997999808	treatment	72	1	MCF10A-GM_5	142	0.1030	586.3	196.0	12428	298.5	0.0234	0.07965	0.1845
Dasatinib	180615_MC_07	1865	0.0922	44	132	12	13	Dasatinib	0.997999808	treatment	72	1	MCF10A-GM_6	176	0.0862	586.3	196.0	12428	298.5	0.0234	0.06283	0.3004
Dasatinib	180615_MC_08	1494	0.1026	46	112	8	19	Dasatinib	0.997999808	treatment	72	1	MCF10A-GM_7	158	0.0956	586.3	196.0	12428	298.5	0.0234	0.07224	0.2365
Dasatinib	180615_MC_08	1489	0.1162	25	151	9	4	Dasatinib	0.997999808	treatment	72	1	MCF10A-GM_8	176	0.1057	586.3	196.0	12428	298.5	0.0234	0.08231	0.2356

|<
<<
Previous
Page 5 of 66
Next
>>
>
101 to 125 of 1647 records
per page:

HMS LINCS Project

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20358)